In addition, kaempferol treatments attenuated the Th2-driven allergic airway disease in an experimental model of asthma induced by OVA challenge by decreasing the production of IL-5 and IL-13 and ameliorating airway hyperresponsiveness induced by OVA challenge. Here, IL13 is linked to asthma.